“The results of our analysis showed that overall, patients with SCLC who survived to receive 3L treatment are a select group ...

Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it ...

Modest absolute reduction in use observed, which increased during peak of shortage; no difference seen in mortality during shortage. (HealthDay News) — The platinum chemotherapy shortage, first ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...